Curaleaf Holdings (CURLF) Cash from Discontinued Operations (2022 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Cash from Discontinued Operations of 2435000.0 for Q4 2024, down 100.58% year-on-year from 422298571.43 in Q1 2024, and down 2559.6% on a QoQ basis from 99000.0 in Q3 2024.
Curaleaf Holdings (CURLF) Cash from Discontinued Operations (2022 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Cash from Discontinued Operations for 3 consecutive years, with 2435000.0 the latest figure, recorded in Q4 2024.
- Quarterly Cash from Discontinued Operations fell 100.58% year-over-year to 2435000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 5503000.0 (up 65.57% YoY) and the FY2025 annual result came in at 14319000.0, down 160.2% from the prior year.
- Cash from Discontinued Operations fell to 2435000.0 in Q4 2024 per CURLF's latest filing, from 99000.0 in the prior quarter.
- Over the last five years, Cash from Discontinued Operations for CURLF reached as high as 9820868000.0 in Q2 2023 and fell as low as 9846000000.0 in Q1 2023.
- A 3-year average of 3019800.0 and a median of 557500.0 in 2023 frame the typical range for Cash from Discontinued Operations.
- Annual changes were most pronounced in 2023 — Cash from Discontinued Operations soared 1141.08% — and 2024, when it sank 176.97%.
- Year by year, Cash from Discontinued Operations stood at 9547000.0 in 2022, then jumped by 87.28% to 1214000.0 in 2023, then tumbled by 100.58% to 2435000.0 in 2024.
- According to Business Quant data, Cash from Discontinued Operations over the past three periods registered 2435000.0, 99000.0, and 7559167000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Curaleaf Holdings | 6.95 Bn | 6.95 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.44 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Sep 30, 2024 | 99,000.00 |
| Sep 30, 2024 | 99,000.00 |
| Jun 30, 2024 | -7.56 Bn |
| Jun 30, 2024 | -7.56 Bn |
| Mar 31, 2024 | 7.56 Bn |
| Mar 31, 2024 | 7.56 Bn |
| Dec 31, 2023 | -1.21 Mn |
| Dec 31, 2023 | -1.21 Mn |
| Sep 30, 2023 | 10.36 Mn |
| Sep 30, 2023 | 10.36 Mn |
| Jun 30, 2023 | 9.82 Bn |
| Jun 30, 2023 | 9.82 Bn |
| Mar 31, 2023 | -9.85 Bn |
| Mar 31, 2023 | -9.85 Bn |
| Dec 31, 2022 | -9.55 Mn |
| Dec 31, 2022 | -9.55 Mn |
| Sep 30, 2022 | 835,000.00 |
| Sep 30, 2022 | 835,000.00 |